Testing a Structured Diet and Lifestyle Program for Type 2 Diabetes in Malaysia
Tests a structured lifestyle program to help adults with type 2 diabetes in Malaysia.
Plain-language title generated from the registry record
Registry title: Remission of Diabetes With Lifestyle Intervention for Malaysian Patients
Key facts
- Where
- Kuala Lumpur and Seremban, MalaysiaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07270068, who can take part
Where in Malaysia
- Hospital PutrajayaKuala Lumpur, MalaysiaTaking people
- Klinik Kesihatan SerembanSeremban, MalaysiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Winnie Chee Siew Swee
- Trial code
- NCT07270068
- Record updated
- 27 March 2026
- Original description
This study aims to evaluate the effectiveness of structured lifestyle intervention to induce remission of Type 2 Diabetes Mellitus (T2DM) among Malaysian adults. The study will also assess the feasibility of implementing this intervention within Malaysian primary and specialist care settings. The study will also examine the economic impact of the TDR intervention through a cost-effectiveness analysis conducted from a societal perspective.Read full original descriptionShow less
Remission of Diabetes With Lifestyle Intervention for Malaysian Type 2 Diabetes Mellitus Patients (ReDiaL-MY) - an Open Label, Randomised Controlled Study
This study aims to evaluate the effectiveness of structured lifestyle intervention to induce remission of Type 2 Diabetes Mellitus (T2DM) among Malaysian adults. The study will also assess the feasibility of implementing this intervention within Malaysian primary and specialist care settings. The study will also examine the economic impact of the TDR intervention through a cost-effectiveness analysis conducted from a societal perspective.
Researchers will compare intensive lifestyle intervention to the usual clinical care.
It is hypothesised that Malaysian adults with T2DM who receive the structured lifestyle intervention will demonstrate a significantly higher rate of diabetes remission compared to those receiving usual care. Furthermore, participants in the intervention group are expected to achieve greater mean weight loss, with a higher proportion attaining a sustained weight loss of at least 10 kilograms, relative to the usual care group. The lifestyle intervention is also anticipated to result in superior glycaemic control, as measured by reductions in glycated haemoglobin (HbA1c), and to be more cost-effective in achieving diabetes remission and reducing long-term healthcare utilization.
Inclusion: Diagnosed diabetes for a duration of < 3 years (diagnosis based on 2 recorded diagnostic-level tests, HbA1C and/or blood glucose); Body mass index (BMI) > 25 kg/m2; HbA1C level above > 6.5% to 9% as per the last routine clinical check within 6 months; Currently being treated with one or more oral glucose lowering drugs.
Exclusion: Recent (last 12 weeks) or current use of medications/meal replacements for weight loss; Chronic treatment with systemic corticosteroids. Use of hormone replacement therapy or oral contraceptives will not lead to exclusion; Requiring hospitalization for depression or are on antipsychotic medications; History of bariatric surgery, small bowel resection, or extensive bowel resection; Severe hypertension on multiple drugs treatment; Cancer requiring treatment for the past 5 years, except of non-melanoma skin cancers or cancers that have been clearly cured; HIV- positive (self-report) due to effects or weight and body composition of HIV and medications treating HIV; Cardiovascular disease (heart attack or procedure within past 3 months or participation in cardiac rehabilitation program within last 3 months, stroke or history/ treatment for transient ischemic attacks in the past 3 months, or documented history of pulmonary embolus for the past 6 months); Proliferative retinopathy and other severe diabetes complications; Diagnosed eating disorder or purging; Recent routine HbA1C of > 9%; Renal disease - eGFR < 60 ml/min (based MDRD) or currently receiving dialysis; Type 1 DM; Type 2 DM on basal or multiple insulin injections; Patients who in the past 6 months have weight loss exceeding 5 kg (such individuals may have difficulty losing additional weight); Alcoholism or any substance abuse; Currently pregnant or nursing and planning to get pregnant.